Muscular Dystrophy Canada
STAR RATINGCi's Star Rating is calculated based on the following independent metrics: |
✔+
FINANCIAL TRANSPARENCY
Audited financial statements for current and previous years available on the charity’s website.
B
RESULTS REPORTING
Grade based on the charity's public reporting of the work it does and the results it achieves.
n/r
DEMONSTRATED IMPACT
The demonstrated impact per dollar Ci calculates from available program information.
NEED FOR FUNDING
Charity's cash and investments (funding reserves) relative to how much it spends on programs in most recent year.
51%
CENTS TO THE CAUSE
For a dollar donated, after overhead costs of fundraising and admin/management (excluding surplus) 51 cents are available for programs.
My anchor
OVERVIEW
About Muscular Dystrophy Canada:
Muscular Dystrophy Canada is a 3-star charity. It has a B results reporting grade, which is average. Its overhead spending is outside Ci’s reasonable range and it has enough reserve funds to cover one year and three months of its annual program costs.
Founded in 1954, Muscular Dystrophy Canada (MDC) supports people living with neuromuscular disorders (NMDs). These conditions are incurable and cause progressive weakness and dysfunction. MDC also funds research to improve treatments and find a cure for NMDs. Muscular Dystrophy Canada has four main programs: Services, Research, Education & Information, and Advocacy.
In the fiscal year ended March 2023 (F2023), MDC spent $3.4m (48% of program spending) on Services. Through this program, MDC offers support to people with NMDs. In F2023, 491 individuals affected by NMDs registered with MDC to access its services. This is a 17% increase from F2022. MDC reports that touchpoints with clients increased by 53% in F2023. Inquiries through MDC’s Research Hotline increased by 89% in F2023. MDC has an Equipment Program that helps cover the costs of assistive devices for people with NMDs.
MDC spent $2.0m (28% of program spending) on Research in F2023. In F2023, research spending funded nine new clinical and translational science research projects, six fellowships, and two Collagen 6-related dystrophy research projects.
MDC spent $1.3m (18% of program spending) on Education & Information in F2023. MDC provides information and learning resources to the neuromuscular community. In F2023, MDC increased Lunch and Learn, Outreach, MuscleFacts, and AccessAbility presentations by 71%. Participants went from 308 in F2022 to 1,461 in F2023.
MDC spent $430k (6% of program spending) on Advocacy in F2023.
My anchor
Results and Impact
Passed in June 2019, Bill C-81, now known as the Accessible Canada Act, lays out a framework for the development of accessibility standards and gives the federal government authority to work with stakeholders to create new accessibility regulations. Muscular Dystrophy Canada reports that it played a role in advocating for this new Bill, along with its partners and the Federal Accessibility Legislation Alliance.
In December 2020, MDC began working with Novartis Pharmaceuticals Canada Inc. to implement newborn screening for spinal muscular atrophy (SMA) across Canada. MDC reports that approximately one in every 10,000 babies are born with SMA in Canada each year. In 2019, newborn screening panels in Canada did not include testing for SMA. By August 2024, all provinces and territories had implemented newborn screening programs for SMA.
While Ci highlights this key outcome, it may not be a complete representation of Muscular Dystrophy Canada’s results and impact. This charity is not yet rated on impact (n/r).
My anchor
Finances
In F2023, Muscular Dystrophy Canada received $7.9m in donations. It also received $5k in government funding and $1.9m in other, non-disclosed income. Administrative costs are 22% of total revenue (excluding investment income) and fundraising costs are 26% of donations. Overhead spending is 49%, which is outside Ci’s reasonable range. For every dollar donated, 51 cents are available for the cause. In F2023, MDC spent $7.1m on its programs (71% of total revenue).
In F2023, MDC had a deficit of $1.4m and spent $27k on capital expenditures.
At the end of F2023, MDC had $8.7m in reserve funds (cash and investments). This is enough to cover 128% or one year and three months of its annual program costs.
This charity profile is an update that was sent to Muscular Dystrophy Canada for review. Changes and edits may be forthcoming.
Updated on August 20th, 2024 by Thea Clark.
Financial Review
Fiscal year ending March
|
2023 | 2022 | 2021 |
|---|---|---|---|
| Administrative costs as % of revenues | 22.4% | 27.3% | 25.6% |
| Fundraising costs as % of donations | 26.1% | 28.0% | 31.0% |
| Total overhead spending | 48.5% | 55.3% | 56.6% |
| Program cost coverage (%) | 123.7% | 144.7% | 261.9% |
Summary Financial StatementsAll figures in $000s |
2023 | 2022 | 2021 |
|---|---|---|---|
| Donations | 7,904 | 6,331 | 5,537 |
| Government funding | 5 | 587 | 1,313 |
| Investment income | 208 | 593 | 1,383 |
| Other income | 1,882 | 428 | 504 |
| Total revenues | 9,999 | 7,939 | 8,736 |
| Program costs | 7,052 | 6,339 | 4,136 |
| Administrative costs | 2,191 | 2,005 | 1,884 |
| Fundraising costs | 2,066 | 1,773 | 1,714 |
| Other costs | 41 | 54 | 54 |
| Total spending | 11,350 | 10,172 | 7,788 |
| Cash flow from operations | (1,350) | (2,233) | 949 |
| Capital spending | 27 | 0 | 0 |
| Funding reserves | 8,720 | 9,174 | 10,832 |
Note: AMORTIZATION: Ci removed amortization from program, administrative, and fundraising costs on a pro-rata basis. DEFERRED REVENUE: Ci adjusted for deferred revenue, affecting total revenue by ($785k) in F2023, ($313k) in F2022, and $967k in F2021. GOVERNMENT FUNDING: Ci used the charity’s T3010 filing with the CRA to remove government funding from donations and other revenue and report this in government funding. MANAGEMENT FEES: Ci included management fees in other costs, increasing total expenses by $41k in F2023, $54k in F2022, and $54k in F2021. UNREALIZED GAIN (LOSS): Ci included unrealized gain (loss) on investments in investment income, affecting total revenue by ($406k) in F2023, ($215k) in F2022, and $941k in F2021.
Salary Information
$350k + |
0 |
$300k - $350k |
0 |
$250k - $300k |
0 |
$200k - $250k |
0 |
$160k - $200k |
1 |
$120k - $160k |
3 |
$80k - $120k |
6 |
$40k - $80k |
0 |
< $40k |
0 |
Information from most recent CRA Charities Directorate filings for F2023
My anchor
Comments & Contact
Comments added by the Charity:
Comment added on August 29th, 2024.
ONGOING PROGRAMS
MUSCULAR DYSTROPHY CANADA (MDC) provides direct support to Canadians affected by Neuromuscular disorders that include: offering emotional support for adapting and coping to Canadians living with a neuromuscular disorder or caring for an individual with a neuromuscular disorder, navigating and accessing healthcare and community services and financial support, providing funding for assistive devices, medical equipment and supports as a last resort that are not funded by government sources, delivering and facilitating peer support and education through caregiver and family retreats, delivering education workshops in social settings, including vocational and learning institutions to enhance awareness and providing tools to enhance full participation at work and school for the Canadian neuromuscular community. Providing consult and support to Canadians to obtain a neuromuscular diagnosis, accessing neuromuscular treatments and therapies, and clinical trials.
Also, Muscular Dystrophy Canada funds peer-reviewed research grants to researchers in universities or other institutions in areas relevant to neuromuscular disorders.
OUR VISION IS TO FIND A CURE FOR MUSCULAR DYSTROPHY.
Until then, we provide support services to the individuals, their families, and their caregivers affected by neuromuscular disorders with the tools and supports to understand their disease and to live their lives to the utmost.
NEW PROGRAMS
Muscular Dystrophy Canada (MDC) funds translational and clinical neuromuscular research grants. MDC funds clinical and post doctorial neuromuscular fellowships. MDC is a copartner and funder of the Neuromuscular Disease Network of Canada NMD4C Home - The Neuromuscular Disease Network for Canada (neuromuscularnetwork.ca). MDC provides education workshops for the medical community, provides education for researchers both early and current career, investigates and identifies neuromuscular outcome measures to be used in clinical settings. MDC conducts natural history studies to be used in decision making concerning access to treatments and therapies. Muscular Dystrophy Canada leads and delivers knowledge translation for all network activities.
Muscular Dystrophy Canada conducts research through its internal research department to help inform changes to public policy including newborn screening for Spinal Muscular Atrophy, early diagnosing of neuromuscular disorders, cost of living with a neuromuscular disorder, patient journey mapping that highlights pain points, emotions and solutions in health care and community service settings from a patient’s perspective. MDC consults and advises government, healthcare and community service decision makers on all findings and provides recommendations to enhance public policy.
Charity Contact
This email address is being protected from spambots. You need JavaScript enabled to view it. Tel: 1-800-567-2873